Medical News

RSS

Tufts Medical Center researchers discover new biological pathway for advanced AMD

Researchers at Tufts Medical Center and collaborators discovered a new biological pathway for advanced age-related macular degeneration that implicates a role of the hepatic lipase gene, LIPC. This discovery will improve understanding of the disease by providing researchers another developmental pathway to explore for prevention and treatment.

13 Apr 2010

U.S. seeks to constrain global AIDS program costs

The Boston Globe: "US officials have asked some AIDS clinics overseas to stop enrolling new patients in a US-sponsored program that provides lifesaving antiretroviral drugs" in an effort to stem the rising costs of this assistance program. This step has triggered concern among some AIDS advocates "that the Obama administration is curtailing its commitment to a program that provides lifesaving drugs for 2.4 million people and that many view as President Bush's most successful foreign policy legacy.

13 Apr 2010

San Diego Union-Tribune examines pharma's growing interest in neglected diseases

The San Diego Union-Tribune examines the pharmaceutical industry's growing interest in developing new treatments for what are known as "neglected diseases."

13 Apr 2010

New tool for retrieving accurate drug side-effect information

It's not uncommon for individuals to take as many as a dozen different prescriptions, each with its own set of possible side effects. If a patient experiences one of the potential hundreds of different adverse reactions such as nausea, headaches, insomnia or heart palpitations, how does the physician quickly and accurately determine which drug is the culprit?

13 Apr 2010

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Researchers may be one step closer to slowing the progression of Alzheimer's disease

Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported by the National Institute of Environmental Health Sciences, part of the National Institutes of Health, shows that by targeting the blood-brain barrier, researchers are able to slow the accumulation of a protein associated with the progression of the illness.

13 Apr 2010

AP examines micro-insurance in Africa

The Associated Press examines the growth of micro-insurance in Africa, "a product accessible to those earning less than $2 a day, who pay tiny weekly premiums of sometimes less than a cent."

13 Apr 2010

UHC announces agreements for executive recruitment services

The University HealthSystem Consortium today announced agreements for executive recruitment services: one with Furst Group, based in Rockford, Ill., and one with Witt/Kieffer, Ford, Hadelman, Lloyd Corporation, based in Oak Brook, Ill. The agreements became effective on February 1, 2010.

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

VLR announces the opening of new U.S. office based in New York

Van Leeuwenhoeck Research, Inc. today announced the opening of a new U.S. office based in New York. Founder and Chief Executive Officer Marcel Wijma will lead the team's effort to expand the VLR platform to provide institutional investors and other professional investors with independent, unbiased research on the real value of innovative life sciences companies.

13 Apr 2010

UPMC Health Plan to host training session on child health- We Can!

UPMC Health Plan will host a two-day training session designed to teach community leaders about We Can! (Ways to Enhance Children's Activity & Nutrition) April 27-28, 2010, at Marriott City Center Hotel, Uptown.

13 Apr 2010

Tailwind device that helps stroke survivors improve arm movement now available

The Tailwind, a new rehabilitation device that helps stroke survivors improve arm movement, even many years after their stroke, is now available on the eve of May as National Stroke Awareness Month. The exercise device empowers stroke survivors to become more independent and enables them to achieve the tasks of daily life.

13 Apr 2010

Loss of lives, hope and trust in the NHS organ donor blunder

In one of the big NHS blunders, nearly 800,000 people who have pledged one or more of their organs for donation may have had their preferences of which organ/s recorded incorrectly for the past 10 years. There are nearly 17 million donors who consent to give all their organs. However some have preferences and withhold consent for some organs like eyes, skin or heart etc. Some had also expressed their wish that their body tissue should not be used in research after their death. This huge error came to public notice in 2009 when the NHS Blood and Transplant started sending out mails to potential donors to check their preferences. Many people wrote back that the information in the records were not right.

13 Apr 2010

Medical Properties Trust announces common stock public offering

Medical Properties Trust, Inc. announced today that it plans to make a public offering of 24 million shares of its common stock. The Company expects to grant the underwriters an option to purchase up to 3.6 million additional shares of common stock to cover over-allotments, if any.

13 Apr 2010

News outlets report on food crisis in Sahel region of Africa

A food crisis is developing across the Sahel region - from Mauritania and Guinea to Nigeria and Sudan - where "[m]illions" of people are facing hunger and malnutrition, aid groups say, afrol News reports.

13 Apr 2010

Aegis Health Group to help Inova Health System increase market share

Aegis Health Group will help Inova Health System, a not-for-profit healthcare system based in northern Virginia, grow market share through its proven business development strategies. Using Aegis' program Inova's seven hospitals will begin working with local employers to better manage the health of their workforce and link hospital-sponsored programs and services with the specific health-related needs of local businesses.

13 Apr 2010

Article One Partners concludes AUTO Patent Studies

Article One Partners, the world's largest patent validation firm, today announced the conclusion of two Patent Studies conducted on behalf of a top global automaker, for which $30,000 has been awarded to two Advisors.

13 Apr 2010

IDF awarded NIH grant for advancing knowledge in PIDD through continuance of USIDNET program

The Immune Deficiency Foundation (IDF) is pleased to announce that it has been awarded the grant "Resources to Assist Investigations in Primary Immunodeficiency Diseases" from the National Institutes of Health (NIH). This grant will allow IDF to continue to advance the detection, understanding, diagnosis and treatment of primary immunodeficiency diseases (PIDD) through their program, the United States Immunodeficiency Network (USIDNET).

13 Apr 2010

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.

13 Apr 2010